• Clinical Evidence

Taking Control of Hyperglycemia to Improve Patient Care: How One Hospital Resolved a Low Benchmark Indicator and Became a Best Practice Site Through Use of EndoTool Glycemic Control Software

Setting: 71-bed full-service community hospital

Objective

This study compares glycemic outcomes before and after implementation of glycemic control software (EndoTool) for patients receiving intravenous insulin, all of whom were previously treated using a paper algorithm.

Setting

71-bed full-service community hospital.

Results

  • Incidence of hypoglycemia <70 mg/dL decreased 80% with EndoTool, from 4% to 0.8% of blood glucose readings.
  • Incidence of hyperglycemia >200 mg/dL decreased 53.8% with EndoTool, from 26% to 12% of blood glucose readings.
  • Mean glucose housewide decreased 21.7 mg/dL with EndoTool, from 183.9 to 162.2 mg/dL, while mean glucose within intensive care units decreased 20.1 mg/dL with EndoTool, from 184.1 to 147.1 mg/dL, achieving top performer status in the Remote Automated Laboratory System (RAL) benchmarking program.
  • Average time to achieve two consecutive blood glucose readings <150 mg/dL was 4.8 hours with EndoTool.
  • Average length of stay for DKA patients decreased from 3.3 to 2.66 days with EndoTool, representing an estimated $3,615.16 cost savings per patient and $74,932.41 cost savings per year.

Conclusions

Use of glycemic control software (EndoTool) allows better and more rapid glucose control than a paper algorithm and, according to physicians and nurses, makes transitioning from intravenous to subcutaneous insulin much easier.

Objective

This study compares glycemic outcomes before and after implementation of glycemic control software (EndoTool) for patients receiving intravenous insulin, all of whom were previously treated using a paper algorithm.

Setting

71-bed full-service community hospital.

Results
  • Incidence of hypoglycemia <70 mg/dL decreased 80% with EndoTool, from 4% to 0.8% of blood glucose readings.
  • Incidence of hyperglycemia >200 mg/dL decreased 53.8% with EndoTool, from 26% to 12% of blood glucose readings.
  • Mean glucose housewide decreased 21.7 mg/dL with EndoTool, from 183.9 to 162.2 mg/dL, while mean glucose within intensive care units decreased 20.1 mg/dL with EndoTool, from 184.1 to 147.1 mg/dL, achieving top performer status in the Remote Automated Laboratory System (RAL) benchmarking program.
  • Average time to achieve two consecutive blood glucose readings <150 mg/dL was 4.8 hours with EndoTool.
  • Average length of stay for DKA patients decreased from 3.3 to 2.66 days with EndoTool, representing an estimated $3,615.16 cost savings per patient and $74,932.41 cost savings per year.
Conclusions

Use of glycemic control software (EndoTool) allows better and more rapid glucose control than a paper algorithm and, according to physicians and nurses, makes transitioning from intravenous to subcutaneous insulin much easier.

References

Authors

Sondra Boecker, RN, CDE; Linda Barhorst, BSN, CDE.

Source

Presented at EndoTool® User Group Meeting.

Year

2013

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This study compares glycemic outcomes before and after implementation of glycemic control software (EndoTool) for patients receiving intravenous insulin, all of whom were previously treated using a paper algorithm.

Setting

71-bed full-service community hospital.

Results
  • Incidence of hypoglycemia <70 mg/dL decreased 80% with EndoTool, from 4% to 0.8% of blood glucose readings.
  • Incidence of hyperglycemia >200 mg/dL decreased 53.8% with EndoTool, from 26% to 12% of blood glucose readings.
  • Mean glucose housewide decreased 21.7 mg/dL with EndoTool, from 183.9 to 162.2 mg/dL, while mean glucose within intensive care units decreased 20.1 mg/dL with EndoTool, from 184.1 to 147.1 mg/dL, achieving top performer status in the Remote Automated Laboratory System (RAL) benchmarking program.
  • Average time to achieve two consecutive blood glucose readings <150 mg/dL was 4.8 hours with EndoTool.
  • Average length of stay for DKA patients decreased from 3.3 to 2.66 days with EndoTool, representing an estimated $3,615.16 cost savings per patient and $74,932.41 cost savings per year.
Conclusions

Use of glycemic control software (EndoTool) allows better and more rapid glucose control than a paper algorithm and, according to physicians and nurses, makes transitioning from intravenous to subcutaneous insulin much easier.

References

Authors

Sondra Boecker, RN, CDE; Linda Barhorst, BSN, CDE.

Source

Presented at EndoTool® User Group Meeting.

Year

2013

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Image
  • Clinical Evidence

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

20 minute read

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

The objective of this study was to evaluate the impact of different blood glucose (BG) target ranges for IV insulin infusions on inpatient glucose metrics, specifically focusing on hypo and hyperglycemic events, duration of IV insulin therapy, and length of stay (LOS) in the hospital.
Image
  • Clinical Evidence

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.